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Abstract: Studies examining post-traumatic stress disorder (PTSD) have either emphasized 
a relationship between PTSD and a systemically pro-inflammatory state or identified a link 
between PTSD and chronic disease. The aim of this study was to evaluate the evidence for a 
relationship between individuals with PTSD and systemic low-grade inflammation that has been 
proposed to underlie chronic disease development in this population. The authors conducted a 
systematic review of the literature (January 2006 to April 2017) in accordance with the PRISMA 
statement in the following four databases: PubMed, MEDLINE, PsycINFO, and SPORTDiscus 
with Full Text. The search strategy was limited to articles published in peer-reviewed journals 
and to human studies. Nine studies measuring systemic inflammation and discussing its role in 
chronic disease development were selected for inclusion in this review. The association between 
markers of systemic inflammation and PTSD was evaluated by the measurement of a variety of 
systemic inflammatory markers including acute-phase proteins, complement proteins, pro- and 
anti-inflammatory cytokines, natural killer cells, and white blood cells. In general, systemic 
inflammatory biomarkers were elevated across the studies in the PTSD groups. There is evidence 
that PTSD is underpinned by the presence of a systemic low-grade inflammatory state. This 
inflammation may be the mechanism associated with increased risk for chronic disease in the 
PTSD population. From this, future research should focus on interventions that help to reduce 
inflammation, such as exercise.
Keywords: cytokines, C-reactive protein, CRP, chronic disease, pro-inflammation, immune 
system
Introduction
Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition that 
manifests after experiencing trauma. Defined as an Axis I disorder in the Diagnostic 
and Statistical Manual of Mental Disorders, fifth edition, PTSD is characterized by 
a number of symptoms such as re-experiencing the traumatic event, avoidance of 
reminders of the traumatic event, negative changes in mood and cognitions, and hyper-
arousal.1,2 These symptoms must persist and cause marked distress and/or functional 
impairment for at least one month.1 The lifetime prevalence rate for PTSD is estimated 
to be 8%, making it the fourth most commonly diagnosed psychiatric disorder, with 
12% and 18% of US soldiers suffering from PTSD upon their return from Afghanistan 
and Iraq, respectively.3,4 Similarly, among Australian war veterans, PTSD is the most 
commonly diagnosed mental health disorder, with a prevalence of 8.1% in Australian 
male soldiers.5
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PTSD places a significant burden on the individual, his 
or her family, and society at large, as not only is it associated 
with multiple negative social consequences such as marital 
difficulties and unemployment but also it seems to be cor-
related with an increased risk of developing chronic somatic 
diseases such as cardiovascular disease (CVD), metabolic 
syndrome, pulmonary disease, autoimmune disorders, and 
other psychiatric disorders that are often associated with 
PTSD.2,6–8 Notably, low-grade systemic inflammation is seen 
as a key mechanism underlying chronic disease and may be 
present too in PTSD, leading to the development of chronic 
diseases in this population.2,9
The underlying psychobiological mechanisms link-
ing PTSD to an increased chronic disease risk have been 
proposed to be altered autonomic nervous system (ANS) 
activity and an impaired reaction of the hypothalamic–pitu-
itary–adrenal (HPA) axis to perceived stress, resulting in a 
chronic low-grade pro-inflammatory state.10 In the context 
of a chronically hyperaroused state (as seen in individuals 
suffering from PTSD), the ANS has been shown to display 
an inappropriate response characterized by a delay in para-
sympathetic nervous system (PNS) reactivation and sym-
pathetic nervous system (SNS) domination continuing long 
after the stressful event has dissipated.11 The consequence 
of prolonged autonomic reactivity in PTSD patients may 
center around the bi-directional relationship between the 
ANS and HPA axis, as represented by vagal activity.2 Con-
sidering that a function of the vagus nerve is to regulate the 
immune system, an attenuated vagal response would fail to 
re-establish PNS dominance at rest. This, in turn, may com-
promise the normal immune profile, exacerbating the risk 
for chronic disease.2 In addition, the dysregulated HPA axis 
may contribute to a chronic low-grade inflammatory state due 
to alterations within the glucocorticoid (GC) receptor itself 
and reduced GC signaling. Changes to GC responsiveness 
may also contribute to allostatic load, resulting in chronic 
disease development.12
Dantzer and colleagues13 proposed that systemic low-
grade inflammation is typically defined by a two- to three-
fold increase in plasma concentrations of pro-inflammatory 
cytokines, such as interleukin (IL)-1, tumor necrosis factor-α 
(TNF-α), and IL-6.14,15 However, the origin of this low-grade 
inflammation remains unclear. Neigh and Ali16 proposed that 
PTSD leads to a pro-inflammatory state as a consequence 
of the dysregulations in the aforementioned ANS and HPA 
axis biological pathways, thereby increasing physical disease 
risk. Conversely, Walker et al17 suggested an alternative 
hypothesis for developing PTSD, emphasizing that chronic 
occupational exposures such as physical exhaustion, smoke, 
heat exposure, and sleep restriction (mainly experienced by 
military veterans and first responders who regularly encounter 
traumatic events) may have a “priming” inflammatory effect 
for the later development of PTSD, ultimately leading to 
chronic somatic illness.
However, this proposed state of low-grade inflamma-
tion characteristic of both PTSD and chronic disease is not 
always indicated. While various studies have demonstrated 
elevations in inflammatory markers in PTSD sufferers, oth-
ers have presented opposing findings.6,18–25 In light of these 
discrepancies, the aim of this systematic review was to assess 
the research that examines the association between PTSD 
and low-grade systemic inflammation.
Material and methods
This systematic review was conducted in accordance with 
the established guidelines from the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
Statement.26,27
Search strategy
An electronic literature search of peer-reviewed journal 
articles was conducted using four databases: PubMed, 
MEDLINE, PsycINFO, and SPORTDiscus. Medical Subject 
Headings (MeSH) were considered in the development of 
the search terms. The search was limited to the English 
language and to human studies. Studies from before 2006 
were excluded. The lead author screened titles, abstracts, 
and methods for relevance based on the selection criteria, 
and all duplicates were removed. Those articles deemed 
relevant were selected for further consideration (Figure 1). 
The search was further limited to peer-reviewed original 
research articles with full text available. Reviews, meta-
analyses, and other types of paper (e.g. author manuscripts, 
letters to the editor) were excluded. A hand search was 
undertaken of the reference lists of relevant articles, and 
those deemed eligible were included with the intent to 
ensure that all articles relevant to the research had been 
captured by the search strategy. The abstracts of the articles 
deemed relevant by the lead author were then indepen-
dently reviewed by a second investigator for relevance. If 
consensus was not reached, the article was moved on to the 
next stage for a review of the full text. The full texts of the 
remaining eligible studies were independently reviewed 
by the investigators against the inclusion and exclusion 
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criteria. Disagreements were discussed until consensus was 
reached in all cases.
Search terminology
The search terms used included: “post-traumatic stress disor-
der” OR “PTSD,” AND “cardiovascular disease” OR “CVD” 
OR “physical health” OR “metabolic disease” OR “immune 
system” OR “inflammation” OR “C-reactive protein” OR 
“CRP” OR “cytokines” OR “leukocytes” OR “white blood 
cells” OR “WBC” OR “acute phase proteins” OR “comple-
ment” OR “innate immunity” OR “hypothalamic pituitary 
adrenal axis” OR “HPA axis.” These were combined using 
the Boolean operators as stated above.
Selection criteria and data extraction
Studies were eligible for inclusion if the following applied: 
(1) they examined trauma leading to PTSD; (2) they exam-
ined the relationship between PTSD, inflammation, and 
chronic disease risk; (3) they had a correlational or longitu-
dinal design (observational, randomized trials); (4) they had 
a control group; and (5) they measured at least one systemic 
inflammatory biomarker.
All papers identified from the initial electronic search 
process were imported into EndNote (version X7; Thomson 
Reuters), where all duplicates were removed. Upon comple-
tion of the title and abstract reviews, a total of 16 articles were 
identified for full-text review, of which nine were identified 
Articles meeting the inclusion
criteria for analysis: n=9
In
cl
ud
ed
E
lig
ib
ili
lty
S
cr
ee
ni
ng
Id
en
tif
ic
at
io
n
Records identified through primary
database searching: n=479
Records after duplicates removed: n=294
Records screened: n=27
Duplicates
removed n=185
Records excluded due to non-
relevant titles: n=267
Records excluded due to
failure of abstract to meet the
following inclusion criteria
       • Criterion 3 (n=11)
Full-text articles excluded
due to not meeting the
following inclusion criteria:
     • Criterion 2 (n=2)
     • Criterion 4 (n=5)
Full-text articles assessed
for eligibility: n=16
Studies included in qualitative
synthesis: n=9
Additional articles identified
through reference lists and
screened against inclusion
criteria: n=0
Figure 1 Schematic representation of the flow of information during the different phases of the systematic review. 
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as meeting the inclusion criteria. The reasons for excluding 
each article were recorded.
Data analysis
After study selection, criteria were followed to maintain the 
evaluation of the studies within narrow standards. The first 
and essential criterion was that all details regarding inflam-
matory marker collection should be verified, with description 
of the instruments, data collection protocol, and methods.
Data extraction of included studies was completed by 
two independent reviewers and compiled into a table. This 
included the following: author and year of publication, 
number of participants, study design, focus of the study, the 
inflammatory markers tested, and the statistical significance 
of study findings.
Risk of bias
Two independent authors used the Physiotherapy Evidence 
Database (PEDro) scale to assess the quality and risk of 
bias of each of the studies identified as eligible (Table 1). 
The PEDro scale has proven constructive validity.28 It is 
an 11-item scale that is used to assess the quality of the 
methodology in studies.29,30 The PEDro scale measures/
assesses the eligibility criteria, randomization, allocation 
processes, similarity of baseline groups, blinding process, 
near-complete data sets obtained for the key outcome, 
between-group statistics reported, and measures of vari-
ability in the selected studies.29 Criterion 1 is used to help 
determine the external validity of the study; criteria 2–9 
are designed to help identify whether the study has internal 
validity; and criteria 10 and 11 assist in determining whether 
there is sufficient statistical information for the results to be 
interpreted appropriately.29 Each of these items was allocated 
a score in relation to the study. A point was allocated if the 
study met the specified criterion and a zero was awarded 
when the item did not. A total score of bias for the study was 
then calculated by adding all of the items together. The risk 
of bias for the studies was established using the criteria from 
the PEDro scale, summating items 2–4 and 7–9. The six cri-
teria that were used in the current review were: (i) adequacy 
of randomization (criterion 2); (ii) allocation concealment 
(criterion 3); (iii) between-group baseline comparability 
(criterion 4); (iv) blinding of outcome assessors (criterion 
7); (v) adequate follow-up (more than 85%) (criterion 8); 
and (vi) intention-to-treat analysis (criterion 9). A score of 
5 or 6 was considered to have a low risk of bias, 3 or 4 a 
moderate risk, and 2 or less a high risk.
Results
Study design and characteristics
In total, 479 records were screened, after the data had been 
filtered and duplicates removed. From these, nine studies 
were identified as meeting the inclusion criteria (Figure 1). 
All of the selected studies were of a cross-sectional design. 
Data are presented in Table 2 with a description of the studies 
(including population and design) according to their focus 
relating inflammation to chronic physical disease in PTSD 
sufferers, the variables that were tested (inflammatory mark-
ers) and the significant statistical findings.
The purpose of all included studies was to investigate 
the systemic inflammatory status of individuals affected by 
PTSD.
Table 1 PEDro scale outcomes
Reference Criterion Total Risk of bias
1 2 3 4 5 6 7 8 9 10 11
Lindqvist et al (2017)6 X 0 0 X 0 0 0 X X X X 6/11 3/6 (moderate)
Lindqvist et al (2014)23 X 0 0 X 0 0 0 X X X X 6/11 3/6 (moderate)
Heath et al (2013)20 X 0 0 0 0 0 0 X X X X 5/11 2/6 (high)
Gola et al (2013)25 X 0 0 X 0 0 0 X X X X 6/11 3/6 (moderate)
Spitzer et al (2010)24 X 0 0 X 0 0 0 X X X X 6/11 3/6 (moderate)
Hoge et al (2009)21 X 0 0 X 0 0 0 X X X X 6/11 3/6 (moderate)
von Känel et al (2007)18 X 0 0 X 0 0 0 X X X X 6/11 3/6 (moderate)
Hovhannisyan et al (2010)22 X 0 0 X 0 0 0 X X X X 6/11 3/6 (moderate)
Bersani et al (2016)19 X 0 0 X 0 0 0 X X X X 6/11 3/6 (moderate)
Notes: Criteria: 1, eligibility criteria were specified; 2, subjects were randomly allocated to groups (in a crossover study, subjects were randomly allocated an order in which 
treatments were received); 3, allocation was concealed; 4, the groups were similar at baseline regarding the most important prognostic indicators; 5, there was blinding of all 
subjects; 6, there was blinding of all therapists who administered the therapy; 7, there was blinding of all assessors who measured at least one key outcome; 8, measures of 
at least one key outcome were obtained from more than 85% of the subjects initially allocated to groups; 9, all subjects for whom outcome measures were available received 
the treatment or control condition as allocated or, where this was not the case, data for at least one key outcome were analyzed by “intention to treat”; 10, the results of 
between-group statistical comparisons are reported for at least one key outcome; 11, the study provides both point measures and measures of variability for at least one 
key outcome. Data from Verhagen et al.29
Abbreviation: PEDro, Physiotherapy Evidence Database.
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Systemic inflammation and post-traumatic stress disorder
Populations assessed
The PTSD populations included in the nine studies included 
in this analysis comprised military veterans and individuals 
who had experienced traumatic accidents or interpersonal 
violence such as physical and sexual assault, although one 
article did not specify the source of trauma.6,18–25 Some studies 
included only male subjects, whereas most consisted of males 
and females, and only one included just females.6,18–25 All 
studies included in this review evaluated various cytokines 
to portray the inflammatory state of the PTSD group against 
that of the control group. Out of these nine studies, all but one 
demonstrated a statistically significant (p≤0.05) difference in 
at least one inflammatory marker in the PTSD compared to 
the control group, with the PTSD population displaying an 
elevated level of pro-inflammatory cytokines, acute-phase 
proteins, and/or white blood cells.25 The research conducted 
by Gola and co-workers25 did not reveal statistically signifi-
cant intergroup differences in basal concentrations of IL-6, 
IL-8, IL-10, TNF-α, or monocyte chemoattractant protein-1 
(MCP-1).
Control for confounding factors
Through the inclusion and exclusion criteria and statisti-
cal analyses, the reviewed studies controlled for the fol-
lowing confounding factors that have known implications 
on the validity of inflammatory marker results: age,6,18–24 
gender,6,18–25 psychiatric co-morbidities,6,18–21,23,25 medica-
tion,6,19,21–25 asthma/allergies,6,23 ethnicity,6,19–21,23,25 educa-
tion,6,19,20,23 length of time since trauma,6,18,19,23 body mass 
index (BMI),6,18–21,23,24 type of trauma,6,19,23,25 alcohol/sub-
stance abuse,18,19,24,25 smoking status,6,18,19,21,23–25 physical 
activity,18,24 employment,20 physical disease,6,18,19,22–25 marital 
status,20 and early life trauma.6,23
Definitions of low-grade inflammation
All studies included in this review conducted research 
investigating the association between PTSD and an 
increased chronic disease risk. Each study aimed to provide 
physiological evidence for this relationship by measuring 
biological inflammatory markers of individuals suffering 
from PTSD versus a control group. However, only three 
out of nine studies clearly defined low-grade inflammation 
(C-reactive protein [CRP] >3 mg/L; 3 standard deviations > 
mean value of IL-6, IL-8, IL-10, TNF-α, and MCP-1).6,24,25 
All of the included studies compared between-group 
inflammatory cytokine levels, acute-phase proteins, and/
or white blood cells, and tested for statistical significance 
(p≤0.05).
Discussion
Normal physiological responses to stress are disrupted in 
individuals suffering from PTSD, as evidenced by an altered 
response from the ANS (attenuation of vagal tone resulting 
in a delayed reactivation of the PNS and sympathetic tone 
domination) and an impaired HPA axis reaction to ongoing 
stress (inhibition of the HPA axis negative feedback loop 
involving cortisol).16 Dennis and co-workers2 emphasized 
that the synchronicity underlying the suggested interaction 
between these two systems is vital to maintaining healthy 
adaptive physiological functioning. Disruptions in these bio-
logical pathways (as noted in PTSD-affected people) appear 
to have downstream effects on other bodily systems such 
as the immune system, as illustrated by chronic low-grade 
inflammation, which may ultimately lead to a higher risk of 
developing a number of physical diseases.16,31
While research has identified the possible biological 
mechanistic impairments that seem to be characteristic 
of PTSD, disagreements remain regarding the potential 
catalysts for developing PTSD. Specifically, it has not been 
established whether an individual is “primed” to develop 
PTSD through an already existing pro-inflammatory state or 
if chronic low-grade inflammation manifests after the devel-
opment of PTSD.17,32 Furthermore, there are discrepancies 
between previous studies’ findings of various inflammatory 
markers compared to a control group. However, while these 
inconsistencies are apparent, it is inarguable that there is a 
significant association between PTSD, inflammation, and 
declining physical health.
In addition to the altered levels of inflammatory markers 
in PTSD sufferers compared to their non-PTSD counterparts, 
all reviewed studies identified a clear risk and prevalence 
of physical co-morbidities of the participants with PTSD. 
Moreover, these studies interpreted chronic inflammation 
(measured through acute-phase proteins such as CRP and 
complement proteins, pro- and anti-inflammatory cytokine 
levels, innate immune cells, and/or white blood cells) as the 
link tying PTSD to chronic disease risk, with CVD having 
the highest prevalence compared to other chronic diseases 
in this population.33 Furthermore, all investigators cited an 
urgent need for the development of interventions that address 
inflammation and chronic disease in PTSD, as its physical 
comorbidities reduce life expectancy by 10–17 years.34
Given the importance of improving the debilitating co-
morbid chronic physical health conditions of PTSD, this 
review contributed by investigating the evidence for systemic 
inflammation in PTSD to substantiate the proposed link 
between PTSD and chronic disease. Despite the majority of 
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the studies demonstrating significant between-group differ-
ences in inflammatory markers, these findings were not unan-
imous. In addition, there was a limited number of studies that 
met the criteria for this review, all of a cross-sectional design, 
and they were not without multiple confounders. Out of the 
nine studies included in this review, one had a relatively small 
(n=28) sample size and all studies had either a moderate or 
high risk of bias according to the PEDro scale.18 Furthermore, 
there were clear differences in the populations comprising 
the control groups between studies. Some studies controlled 
for trauma exposure in both groups, while the non-PTSD 
groups in the remaining studies included participants who 
had no trauma record whatsoever.6,18–25 As a consequence, 
regarding the studies that did not have a trauma-exposed 
control group, the notion that trauma exposure is the factor 
affecting inflammation cannot be dismissed.18 Similarly, 
only three studies took into account timing of exposure to 
the trauma and none of the studies investigated the possible 
effect of the duration of participants’ PTSD status on systemic 
inflammation.6,22,23 Having said that, one of the reviewed 
studies measured the effect of repeated exposure to trauma 
on inflammation in PTSD participants and concluded that the 
number of traumatic exposures was directly proportional to 
systemic inflammation.25 
As there is a multitude of variables to account for in psy-
choneuroimmunological research, this review recognizes that 
demonstrating psychobiological relationships and the conse-
quential effects if their underlying mechanisms are impaired 
is relatively new; as such, the investigations included in this 
review have provided crucial information regarding prelimi-
nary psychological and physiological information in regard 
to systemic low-grade inflammation and chronic disease 
prevalence in the PTSD-afflicted population.35 These studies 
have established the foundation upon which further research 
can build as a means to provide individuals suffering from 
PTSD with novel, long-term, effective treatment plans not 
only to improve the psychological symptoms of PTSD but 
also to reduce the physical morbidity and early mortality 
rates demonstrated in this population.36 The universal theme 
embedded across the reviewed studies was the clear associa-
tion between PTSD and systemic low-grade inflammation.
PTSD and inflammation
The major finding regarding the association between inflam-
mation and PTSD was the significant difference in specific 
pro- and anti-inflammatory cytokines, acute-phase proteins, 
innate immune cells, and/or white blood cells between the 
PTSD-affected and unaffected, “healthy” groups. The most 
commonly tested acute-phase proteins, cytokines, innate 
immune cells, and white blood cells included CRP, IL-6, 
IL-10, TNF-α and IFN-γ, T lymphocytes, various comple-
ment components (classical and alternative pathways), and 
natural killer (NK) cells. Some of these biomarkers, such 
as CRP, IL-6, TNF-α, and IFN-γ, are known to display 
pro-inflammatory effects, while IL-10 is recognized as anti-
inflammatory in nature.29,33 None of the reviewed studies 
found a statistically significant inter-group difference in 
IL-10.
Considering the studies that measured CRP, IL-6, TNF-α, 
and IFN-γ in PTSD sufferers versus non-PTSD sufferers, all 
but one found significantly higher levels of pro-inflammatory 
markers in the PTSD group compared with the non-PTSD 
group. While the outlying studies by Gola et al25 and von 
Känel et al18 argued for an overall pro-inflammatory state in 
individuals with PTSD, they did not find (contrary to their 
hypothesis) significant between-group differences in pro-
inflammatory biomarkers. However, with regard to IL-4 and 
IL-6, none of the included studies took into account their dual 
role as both pro- and anti-inflammatory cytokines. This makes 
interpretation of the between-group measurements of IL-4 
and IL-6 levels difficult because it is unclear whether they are 
acting as a pro- or anti-inflammatory cytokines in PTSD.37,38
The findings highlighted in this review are clinically 
important in the treatment of PTSD, because if an ongo-
ing systemic low-grade inflammatory state is consistently 
detected in this population, treatment may then be directed 
towards managing the under-regulated inflammatory aspects 
of the disease to provide symptom relief and potential co-
morbid chronic disease prevention.
PTSD and chronic disease risk
As evident in the included studies, PTSD is associated with 
overall elevated levels of various immune/inflammatory 
markers. Similarly, this pro-inflammatory state is also pres-
ent in the pathogenesis of chronic physical illnesses such as 
CVD, insulin resistance, metabolic syndrome, pulmonary 
disorders, and autoimmune diseases.9,32 In the nine studies 
included for this review, it was the overarching view that these 
inflammatory processes found in both PTSD and chronic 
disease are related, and the catalyst for this elevated systemic 
inflammation may be stress induced.9
The key findings presented were that acquiring PTSD 
leads to an increased risk for developing physical co-mor-
bidities, with cardiovascular, metabolic, musculoskeletal, 
dermatological, and pulmonary diseases being diagnosed in 
this population most frequently.39
From the evidence provided linking PTSD, inflamma-
tion, and chronic disease risk, it is essential to ensure that 
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treatments are designed for this population such that the 
outcome provides a better quality of life for individuals 
with PTSD.
Heterogeneity of included studies
Of the studies included, it is clear that there is a link between 
PTSD, chronic disease risk, and a chronically pro-inflamed 
state. However, the large degree of heterogeneity between 
the studies cannot be ignored. There was a glaring absence 
of an included definition of “low-grade inflammation” in the 
majority of studies.18–23 The exclusion of this definition makes 
it difficult to determine the exact significance of the inter-
group results in the context of inflammatory marker levels. In 
addition, all of the included studies measured inflammatory 
markers through the collection of plasma samples; however, 
recent research has shown that inflammatory markers col-
lected via saliva more accurately depict the dysregulated 
immune state of PTSD participants.40 There was also a lack 
of uniformity in psychological assessment and biomarker 
collection methods, as well as variations in the time of day 
at which samples were collected. These disparities make it 
difficult to directly compare the studies, as different methods 
for assessment and collection would have differing reliability 
and/or sensitivity, and diurnal variance in cytokine collection 
would certainly confound results as cytokine concentrations 
fluctuate throughout the day.18
There were also inconsistencies between the studies 
included in this review and the confounding variables known 
to influence inflammation. These confounders include age, 
gender, ethnicity, education, marital status, employment, 
medications, psychiatric co-morbidities, asthma/allergies, 
physical co-morbidities, early life trauma, time since trauma, 
trauma type, BMI, alcohol/substance abuse, smoking status, 
and physical activity. This review recognizes that the included 
studies did attempt to control for various combinations of 
the aforementioned confounders (statistically through their 
results or via their inclusion/exclusion criteria) as well as 
the difficulty in controlling for all of these confounding 
factors; however, the reliability of the results still remains 
questionable. Without total control over the confounding 
variables, determining the exact cause of the demonstrated 
pro-inflammatory state in individuals with PTSD becomes 
difficult. Nonetheless, the results still displayed inconsis-
tencies, with some studies indicating non-significance of 
results after controlling for certain confounding factors and 
the remaining studies demonstrating significance even after 
accounting for many of the above confounders.6,18–25 Notably, 
the studies that did not consistently demonstrate statistically 
significant findings for elevation in all inflammatory markers 
in the PTSD participants still reported the presence of an 
overall pro-inflammatory state in this population compared to 
their healthy counterparts. The researchers from both studies 
attribute this conclusion to a suggested correlation between 
PTSD symptom severity and TNF-α levels in the PTSD 
sample, such that the more severe the PTSD symptoms, the 
higher the levels of TNF-α.18,25
Based upon the limitations discussed above, it appears 
that there is a definite need for future studies to establish 
inter-study homogeneity by defining “low-grade inflam-
mation,” controlling assessment and collection methods, 
standardizing the time of day at which samples are collected, 
and accounting for the various confounding factors to the 
best of their abilities.
Clinical applications
There is a growing body of literature suggesting that there 
is a strong association between PTSD and chronic disease. 
Furthermore, this association may be independent of mul-
tiple confounding variables such as age, depression, and/
or co-morbid anxiety disorders.41 There is agreement that 
PTSD appears to involve shifts within the central nervous 
system and immune/inflammatory processes, such that the 
effects of PTSD-related chronic stress causes a dysregulation 
of these systems, which then incurs an elevated risk for the 
subsequent development of multiple chronic illnesses with 
an inflammatory pathophysiology.42,43
Current standard PTSD management lies within the 
psychiatric parameters of this disorder.43 However, there is a 
staggering lack of treatment targeting the co-morbid physical 
disease risk factors that ultimately result in overall impair-
ment of long-term health and well-being.42 In addition, there 
is limited research examining acute physiological recovery 
from stress in PTSD sufferers.43 Such research will provide 
clarity on the appropriateness of their acute stress response 
that will help in the development of more effective treatment 
plans for this population.
Given that PTSD is not solely a psychiatric disorder, 
and the nature of its associated physical co-morbidities with 
inflammatory underpinnings, it is essential to develop appro-
priate cardiometabolic preventive therapy and treatment plans 
(in conjunction with therapeutic management) that reduce 
these long-term deleterious health outcomes.
Future research
Despite the research-based evidence of a chronic, low-grade 
pro-inflammatory state in individuals with PTSD and its link 
 
Jo
ur
na
l o
f I
nf
la
m
m
at
io
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
92
.1
6.
10
8 
on
 1
2-
De
c-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Inflammation Research 2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
120
Speer et al
to long-term adverse health outcomes, the development of 
appropriate treatment methods to target these findings is yet 
to be established. As previously stated, the underlying link 
between PTSD and chronic somatic disease is illustrated 
by impaired psycho-physiological mechanisms leading 
to ongoing inflammation in these individuals. Therefore, 
treatment of both the psychological symptoms and physical 
co-morbidities in this population should address this chroni-
cally inflamed state.
Conclusion
PTSD is a severely crippling disorder that manifests in active-
duty combat soldiers, military veterans, first responders and 
civilians alike, resulting in a number of long-term psychologi-
cal and physical adverse health outcomes. The common feature 
underlying these conditions is a chronically elevated inflam-
matory state. Considering the devastating effects that PTSD 
has on the individual, his or her family, and society at large, 
there is a critical need to better understand the exact causes of 
PTSD and the regulatory systems/biological factors involved 
that contribute to the inflammatory state seen in PTSD. Once 
this has been achieved, implementation of an effective, easily 
accessible adjuvant treatment to usual care can be put in place 
to improve the quality of life of the PTSD population.
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